Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors.

@article{Goel2009PhaseIS,
  title={Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors.},
  author={Rakesh Goel and Eric Chen and Stephen A Welch and Scott A. Laurie and Lillian L. Siu and Derek J. Jonker and Ramaprasad Srinivasan and Lisa Wang and Percy S. Ivy and Amit Manulal Oza},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={e13509}
}
e13509 Background: E7389 (E) is a synthetic analogue of halichondrin B, an investigational tubulin-based antimitotic drug. Gemcitabine (G) is a nucleoside analogue clinically active in several human tumours. These two drugs exhibit synergistic cytotoxic effects against the H522 non-small cell lung cancer (NSCLC) xenografts. METHODS A phase I study of these two drugs in combination was initiated in patients with advanced solid tumours. Two prior chemotherapy regimens for metastatic disease… CONTINUE READING